[
    [
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)向激励对象首次授予限制性股票1272.79万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "限制性股票",
                    "激励计划"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)向激励对象首次授予限制性股票1272.79万股",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：确认政策底 行业迎来布局良机",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策底",
                    "布局良机"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：确认政策底 行业迎来布局良机",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值",
            "features": {
                "keywords": [
                    "医药生物",
                    "景气度",
                    "竞争力",
                    "外需逻辑",
                    "诺禾致源"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]